Iran faces widening medicine shortages as sanctions tighten grip

Iran's healthcare system is grappling with acute shortages of critical medicines as tightened economic sanctions restrict access to pharmaceuticals and raw materials needed for domestic production. Citizens across the country report difficulty obtaining drugs for chronic conditions, cancer treatment, and other life-saving therapies, with prices climbing beyond the reach of many ordinary Iranians.

The supply crisis stems from international sanctions that have severely limited Iran's ability to import medicines and manufacturing components while constraining foreign currency reserves needed for purchases. Hospitals and pharmacies nationwide have reported depleted stocks of commonly used medications, forcing patients to seek alternatives or forgo treatment entirely.

Iranian health authorities acknowledge the severity of the situation but have sought to reassure the public about the sector's long-term viability. Officials have emphasized ongoing domestic production efforts and stated that the pharmaceutical industry retains sufficient capacity to meet essential needs, despite current distribution and affordability challenges.

The medicine shortage compounds existing healthcare pressures across Iran and underscores the humanitarian impact of prolonged economic isolation on civilian populations dependent on imported therapeutics.